The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
暂无分享,去创建一个
Michael Tanen | Matthew E. Kennedy | Wei Li | Xia Chen | Lynn A. Hyde | A. Stamford | J. Cumming | R. Hodgson | M. Forman | K. Cox | L. Ereshefsky | M. Troyer | M. Kennedy | R. Kuvelkar | E. Parker | J. Palcza | Xia Chen | L. Hyde | J. Stone | Julie A. Stone | Reshma Kuvelkar | Kathleen Cox | John Palcza | Larry Ereshefsky | Hong Mei | Matthew D. Troyer | Eric M. Parker | Andrew W. Stamford | Jared N. Cumming | Marissa F. Dockendorf | Michael Egan | Robert A. Hodgson | Stanford Jhee | Huub J. Kleijn | Britta A. Mattson | Jack D. Scott | Jack L. Tseng | Mark S. Forman | M. Dockendorf | H. Kleijn | M. Tanen | Mike F. Egan | S. Jhee | J. Tseng | B. A. Mattson | H. Mei | Wei Li
[1] R. Vassar,et al. Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.
[2] J. Olney,et al. Cathepsin D Deficiency Induces Persistent Neurodegeneration in the Absence of Bax-Dependent Apoptosis , 2007, The Journal of Neuroscience.
[3] B. de Strooper,et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells , 2013, Proceedings of the National Academy of Sciences.
[4] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[5] P. Steiner,et al. Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein* , 2014, The Journal of Biological Chemistry.
[6] Lynn A. Hyde,et al. Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates. , 2016, Journal of medicinal chemistry.
[7] Lingyan Wang,et al. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.
[8] P. Wong,et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects , 2014, Journal of neurochemistry.
[9] P. Saftig,et al. Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.
[10] Suresh Babu,et al. Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.
[11] Y. Shitaka,et al. Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice , 2012, The Journal of Neuroscience.
[12] Manuel Buttini,et al. Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice* , 2007, Journal of Biological Chemistry.
[13] Graham M. West,et al. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors , 2016, Nature Communications.
[14] B. de Strooper,et al. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015, Annual review of pharmacology and toxicology.
[15] K. Lyons,et al. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[16] James E Audia,et al. Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.
[17] S. Wakatsuki,et al. Roles of Meltrin b / ADAM 19 in the Processing of Neuregulin * , 2001 .
[18] B. Strooper,et al. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease , 2016, Trends in Neurosciences.
[19] P. Wong,et al. Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.
[20] Rudi D'Hooge,et al. Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.
[21] J. Hardy,et al. A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.
[22] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[23] D. Theil,et al. Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice , 2016, Scientific Reports.
[24] B. de Strooper,et al. Antagonistic Effects of BACE1 and APH1B-γ-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse , 2015, Cell reports.
[25] Christopher G. Wilson,et al. BACE1 Deficiency Causes Altered Neuronal Activity and Neurodegeneration , 2010, The Journal of Neuroscience.
[26] R. Bateman,et al. CNS Amyloid-β, Soluble APP-α and -β Kinetics during BACE Inhibition , 2014, The Journal of Neuroscience.
[27] M. Danhof,et al. Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[28] Dietmar R. Thal,et al. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.
[29] D. Holtzman,et al. Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.
[30] Jochen Herms,et al. η-Secretase processing of APP inhibits neuronal activity in the hippocampus , 2015, Nature.
[31] M. Fielden,et al. Retinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat , 2015, Toxicologic pathology.
[32] B. de Strooper,et al. The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid-β (Aβ) Aggregation* , 2014, The Journal of Biological Chemistry.
[33] D. Selkoe,et al. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.
[34] S. Wakatsuki,et al. Roles of Meltrin β/ADAM19 in the Processing of Neuregulin* , 2001, The Journal of Biological Chemistry.
[35] R. Berry,et al. β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis , 2007, The Journal of Neuroscience.
[36] Alonso Emilio,et al. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment , 2012, EMBO molecular medicine.
[37] Qin Jiang,et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. , 2016, Journal of medicinal chemistry.
[38] M. Ohno,et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice , 2007, Neurobiology of Disease.
[39] J. Morris,et al. Fluctuations of CSF amyloid-β levels , 2007, Neurology.
[40] B. Strooper,et al. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015 .
[41] R. Aebersold,et al. Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. , 2011, Cell metabolism.
[42] K. Blennow,et al. BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System , 2012, PloS one.
[43] R. Dean,et al. The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans , 2015, The Journal of Neuroscience.
[44] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.